CA2969024C - Adjuvant composition - Google Patents

Adjuvant composition Download PDF

Info

Publication number
CA2969024C
CA2969024C CA2969024A CA2969024A CA2969024C CA 2969024 C CA2969024 C CA 2969024C CA 2969024 A CA2969024 A CA 2969024A CA 2969024 A CA2969024 A CA 2969024A CA 2969024 C CA2969024 C CA 2969024C
Authority
CA
Canada
Prior art keywords
nucleic acid
rna
cancer
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2969024A
Other languages
English (en)
French (fr)
Other versions
CA2969024A1 (en
Inventor
Tsukasa Seya
Misako Matsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Of Advanced Immunotherapy
Original Assignee
Institute Of Advanced Immunotherapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Advanced Immunotherapy filed Critical Institute Of Advanced Immunotherapy
Publication of CA2969024A1 publication Critical patent/CA2969024A1/en
Application granted granted Critical
Publication of CA2969024C publication Critical patent/CA2969024C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2969024A 2014-12-02 2015-12-01 Adjuvant composition Active CA2969024C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-244421 2014-12-02
JP2014244421A JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物
PCT/JP2015/083825 WO2016088784A1 (ja) 2014-12-02 2015-12-01 アジュバント組成物

Publications (2)

Publication Number Publication Date
CA2969024A1 CA2969024A1 (en) 2016-06-09
CA2969024C true CA2969024C (en) 2022-05-24

Family

ID=56091725

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2969024A Active CA2969024C (en) 2014-12-02 2015-12-01 Adjuvant composition

Country Status (7)

Country Link
US (1) US10105385B1 (enExample)
EP (1) EP3228322B8 (enExample)
JP (1) JP6453063B2 (enExample)
CN (1) CN106999573B (enExample)
AU (1) AU2015356078B2 (enExample)
CA (1) CA2969024C (enExample)
WO (1) WO2016088784A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210252131A1 (en) * 2016-06-24 2021-08-19 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190034210A (ko) 2016-07-27 2019-04-01 가부시키가이샤 츠기츠기세다이 이노베이숀 가이하츠 암 면역 아쥬반트
EP3509629A1 (en) * 2016-09-06 2019-07-17 H. Hoffnabb-La Roche Ag Mhc-bound peptide arrays and methods of use thereof
EP4632069A1 (en) 2022-12-05 2025-10-15 Aomori Yamada Gakuen Educational Corporation Nucleic acid adjuvant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064358A2 (en) * 1998-03-26 2001-01-03 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
WO2012014945A1 (ja) * 2010-07-28 2012-02-02 国立大学法人北海道大学 アジュバント活性を有する新規核酸およびその利用
CN102000330B (zh) * 2010-09-14 2012-08-29 中国人民解放军第二军医大学 一种核酸疫苗佐剂及其构建方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210252131A1 (en) * 2016-06-24 2021-08-19 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
US12533404B2 (en) * 2016-06-24 2026-01-27 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases

Also Published As

Publication number Publication date
EP3228322B1 (en) 2019-04-10
CN106999573A (zh) 2017-08-01
AU2015356078B2 (en) 2021-09-16
US20180280425A1 (en) 2018-10-04
EP3228322A4 (en) 2018-05-30
WO2016088784A1 (ja) 2016-06-09
AU2015356078A1 (en) 2017-06-29
EP3228322B8 (en) 2019-06-19
CN106999573B (zh) 2021-10-19
CA2969024A1 (en) 2016-06-09
JP2016108250A (ja) 2016-06-20
EP3228322A1 (en) 2017-10-11
JP6453063B2 (ja) 2019-01-16
US10105385B1 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
ES2992653T3 (en) Methods of preparing lipid nanoparticles
KR102527941B1 (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
EP2599866B1 (en) Novel nucleic acid having adjuvant activity and use thereof
ES3054460T3 (en) Therapeutics for the treatment of neurodegenerative disorders
US11931409B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
JP2020506189A (ja) Ｒｎａ癌ワクチン
CA2969024C (en) Adjuvant composition
KR20200028392A (ko) 질환의 치료를 위한 sting-의존성 활성화제
WO2025016479A1 (zh) 核酸载体、核酸药及其制备方法和应用
CN118265791A (zh) 用于cGAS-STING和STAT3通路调节以对癌症进行免疫治疗性治疗的球形核酸
US20240200064A1 (en) Gene therapy for inflammatory conditions
JP2025536260A (ja) 細胞透過性抗体の組成物および使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200902

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241119